Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Regulatory News (VRP)

  • There is currently no data for VRP

PDMR Dealing

2 Mar 2017 09:36

RNS Number : 3484Y
Verona Pharma PLC
02 March 2017
 

 

Verona Pharma plc

 

PDMR Dealing

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Dr. Jan-Anders Karlsson

2

Reason for the notification

a)

Position/status

 

 

Chief Executive Officer

b)

Initial notification/Amendment

 

 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Verona Pharma plc

b)

LEI

 

n/a

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of 5 pence each

GB00BYW2KH80

b)

Nature of the transaction

 

 

Jan-Anders Karlsson purchased 19,750 Ordinary Shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

149 pence per Ordinary Share

12,000 Ordinary Shares

149 pence per Ordinary Share

7,750 Ordinary Shares

d)

Aggregated information

- Aggregated volume

- Price

19,750 Ordinary Shares at 149 pence per Ordinary Share

 

e)

Date of the transaction

12,000 Ordinary Shares on 28 February 2017 and 7,750 Ordinary Shares on 1 March 2017

f)

Place of the transaction

 

 

London Stock Exchange, AIM

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHEANDAEDFXEEF
Date   Source Headline
13th Sep 20167:00 amPRNHalf-year Report
12th Sep 20167:00 amPRNAppointment of Vikas Sinha as Non-Executive Director
30th Aug 20167:00 amPRNData on RPL554 to be presented at ERS Congress
10th Aug 20169:59 amPRNNotice of Results
9th Aug 20162:16 pmRNSDirector Dealing
5th Aug 20169:27 amRNSHolding(s) in Company
4th Aug 20163:26 pmPRNGrant of Share Options
4th Aug 20168:45 amRNSHolding(s) in Company
3rd Aug 20169:03 amRNSHolding(s) in Company
3rd Aug 20168:43 amRNSHolding(s) in Company
3rd Aug 20168:37 amRNSHolding(s) in Company
2nd Aug 20164:26 pmRNSHolding(s) in Company - Replacement
2nd Aug 201611:26 amRNSHolding(s) in Company
1st Aug 20163:57 pmRNSHolding(s) in Company
1st Aug 201611:40 amRNSHolding(s) in Company
1st Aug 201611:20 amRNSHolding(s) in Company
29th Jul 20168:06 amPRNAdmission of Placing Shares
22nd Jul 201611:32 amPRNResult of GM
1st Jul 20168:00 amPRNNotice of GM
27th Jun 20161:42 pmPRNResult of AGM
20th Jun 20167:00 amPRNProposed Placing and Notice of General Meeting
17th Jun 20164:54 pmPRNProposed Placing and Notice of General Meeting
3rd Jun 20165:26 pmPRN2015 Annual Report and Accounts, Notice of AGM
3rd Jun 20167:00 amPRNFinal Results
27th May 20162:48 pmPRNNotice of Results
10th May 20167:00 amPRNAdd-on Phase II RPL554 study
4th May 20167:00 amPRNVerona to present RPL554 at the ATS Conference
19th Apr 20163:16 pmPRNChange of Registered Office
15th Apr 20164:08 pmRNSHolding(s) in Company
21st Mar 20167:00 amPRNVerona Pharma: 2015 in review
15th Mar 20167:00 amPRNPositive results from RPL554 dose-finding study
10th Feb 20162:47 pmPRNGrant of Share Options
21st Jan 201612:24 pmRNSDirector Dealing
11th Jan 20167:00 amPRNDirectorate Change
3rd Dec 20154:02 pmPRNDirector Dealing
1st Dec 20155:11 pmRNSHolding(s) in Company
11th Nov 20157:00 amPRNRPL554 paper published in American Journal of Physiology
5th Nov 20157:00 amPRNPatient enrolment completed in RPL554 PhIIa studies
14th Oct 20157:00 amPRNStart of RPL554 Phase IIa combination study
8th Oct 201511:30 amPRNRPL554 data presented at North American CF Conference
29th Sep 20157:00 amPRNPositive headline data from RPL554 study
8th Sep 20157:00 amPRNBoard Changes
8th Sep 20157:00 amPRNHalf-yearly Report
27th Aug 20157:00 amPRNNotice of Results
7th Jul 20154:45 pmPRNDirector Dealing
17th Jun 20155:02 pmPRNDirector Dealings
12th Jun 20157:00 amPRNSecondary listing in Germany
11th Jun 20151:00 pmPRNResult of AGM
11th Jun 20157:00 amPRNRPL554 Phase 2a trial started
8th Jun 20157:00 amPRNRPL554 MAD study complete

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.